Literature DB >> 3780825

Oral bioavailability of high-dose metoclopramide.

W B Taylor, D N Bateman.   

Abstract

The oral bioavailability of high-dose metoclopramide was studied in 12 patients, who received oral or intravenous (i.v.) metoclopramide in random order with each of 2 consecutive courses of cytotoxic chemotherapy. The terminal half-life of metoclopramide was 7.1 +/- 0.4 h (mean +/- SEM) and was not affected by the route of drug administration. Mean bioavailability was 86.6 +/- 4.7% and the range (65-118%) was less than that reported for standard doses. Neither half-life nor bioavailability was significantly correlated with age. Adverse effects were mild and were similar for both oral and iv metoclopramide. Oral high-dose metoclopramide, given in the same doses as for i.v. administration, should therefore be as effective as the i.v. regimen and may be easier to administer.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3780825     DOI: 10.1007/bf00870983

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  8 in total

1.  Clinical pharmacokinetics of high-dose metoclopramide in cancer patients receiving cisplatin therapy.

Authors:  J E McDermed; J L Cohen; C Joseph; S B Strum
Journal:  J Clin Oncol       Date:  1985-10       Impact factor: 44.544

2.  Pharmacokinetics and efficacy of high-dose metoclopramide given by continuous infusion for the control of cytotoxic drug-induced vomiting.

Authors:  W B Taylor; S J Proctor; D N Bateman
Journal:  Br J Clin Pharmacol       Date:  1984-11       Impact factor: 4.335

3.  Oral metoclopramide and cisplatin chemotherapy.

Authors:  M B Garnick
Journal:  Ann Intern Med       Date:  1983-07       Impact factor: 25.391

4.  The pharmacokinetics of metoclopramide in man with observations in the dog.

Authors:  D N Bateman; C Kahn; D S Davies
Journal:  Br J Clin Pharmacol       Date:  1980-04       Impact factor: 4.335

5.  Single-dose pharmacokinetics of metoclopramide.

Authors:  L M Ross-Lee; M J Eadie; W D Hooper; F Bochner
Journal:  Eur J Clin Pharmacol       Date:  1981       Impact factor: 2.953

6.  The pharmacokinetics, bioequivalence and bioavailability of different formulations of metoclopramide in man.

Authors:  W Block; A Pingoud; M Khan; P Kjellerup
Journal:  Arzneimittelforschung       Date:  1981

7.  [Preliminary pharmacokinetics of metoclopramide in humans. Plasma levels following a single oral and intravenous dose (author's transl)].

Authors:  D Schuppan; I Schmidt; M Heller
Journal:  Arzneimittelforschung       Date:  1979

8.  Antiemetic efficacy of high-dose metoclopramide: randomized trials with placebo and prochlorperazine in patients with chemotherapy-induced nausea and vomiting.

Authors:  R J Gralla; L M Itri; S E Pisko; A E Squillante; D P Kelsen; D W Braun; L A Bordin; T J Braun; C W Young
Journal:  N Engl J Med       Date:  1981-10-15       Impact factor: 91.245

  8 in total
  7 in total

Review 1.  Pharmacokinetic optimisation of antiemetic therapy.

Authors:  M Campbell; D N Bateman
Journal:  Clin Pharmacokinet       Date:  1992-08       Impact factor: 6.447

2.  Pharmacokinetics of metoclopramide in patients with liver cirrhosis.

Authors:  E Magueur; H Hagege; P Attali; E Singlas; J P Etienne; A M Taburet
Journal:  Br J Clin Pharmacol       Date:  1991-02       Impact factor: 4.335

3.  High-dose metoclopramide by infusion: a double-blind study of plasma concentration-effect relationships in patients receiving cancer chemotherapy.

Authors:  W B Taylor; J M Simpson; D N Bateman
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

4.  Population analysis of the pharmacokinetic variability of high-dose metoclopramide in cancer patients.

Authors:  J Grevel; B Whiting; A W Kelman; W B Taylor; D N Bateman
Journal:  Clin Pharmacokinet       Date:  1988-01       Impact factor: 6.447

5.  Minimal biliary excretion and enterohepatic recirculation of metoclopramide in patients with extrahepatic cholestasis.

Authors:  A Hellstern; D Hellenbrecht; R Saller; M Gatzen; G Achtert; P Brockmann; H J Hausleiter
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

6.  Dopamine receptor blockade improves pulmonary gas exchange but decreases exercise performance in healthy humans.

Authors:  Vincent Tedjasaputra; Tracey L Bryan; Sean van Diepen; Linn E Moore; Melissa M Bouwsema; Robert C Welsh; Stewart R Petersen; Michael K Stickland
Journal:  J Physiol       Date:  2015-06-08       Impact factor: 5.182

7.  Population Pharmacokinetics of Metoclopramide in Infants, Children, and Adolescents.

Authors:  Shufan Ge; Susan R Mendley; Jacqueline G Gerhart; Chiara Melloni; Christoph P Hornik; Janice E Sullivan; Andrew Atz; Paula Delmore; Adriana Tremoulet; Barrie Harper; Elizabeth Payne; Susan Lin; Jinson Erinjeri; Michael Cohen-Wolkowiez; Daniel Gonzalez
Journal:  Clin Transl Sci       Date:  2020-05-27       Impact factor: 4.689

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.